Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced CEO Jay R. Luly, Ph.D., will participate in two fireside chats in June 2022. The events include the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the JMP Securities Life Sciences Conference on June 16 at 9:30 a.m. ET. Webcast links will be available on Enanta's website, along with replays for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with candidates for RSV, COVID-19, and HBV under development.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two fireside chats being webcast in June:

• Jefferies Healthcare Conference: Fireside Chat at 9:00 a.m. ET on June 9, 2022
• JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on June 16, 2022

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005111/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What events is Enanta Pharmaceuticals participating in June 2022?

Enanta Pharmaceuticals will participate in the Jefferies Healthcare Conference on June 9 at 9:00 a.m. ET and the JMP Securities Life Sciences Conference on June 16 at 9:30 a.m. ET.

How can I watch the Enanta Pharmaceuticals fireside chats?

The fireside chats can be viewed live on Enanta's website in the 'Events and Presentations' section, with replays available for 30 days.

What is the focus of Enanta Pharmaceuticals' research?

Enanta Pharmaceuticals focuses on the discovery and development of small molecule drugs for viral infections and liver diseases, including candidates for RSV, COVID-19, and hepatitis B.

What is Enanta Pharmaceuticals' stock symbol?

The stock symbol for Enanta Pharmaceuticals is ENTA.